Quizartinib Sparks Remission in Some Patients With Resistant AML
December 18th 2012Quizartinib, a novel tyrosine kinase inhibitor, demonstrated a clinical benefit in patients with a particularly deadly form of acute myeloid leukemia in results of a phase II study presented during the 54th Annual ASH Meeting.
Read More
Novel JAK2 Inhibitor Shows Promise as Myelofibrosis Therapy
December 14th 2012An investigational, selective JAK2 inhibitor known as SAR302503 reduced spleen size in patients with myelofibrosis, according to phase II data presented at the 2012 American Society of Hematology Annual Meeting and Exposition.
Read More
Ibrutinib Performance in CLL Patients Hailed
December 13th 2012The novel targeted agent ibrutinib has demonstrated dramatic activity in hard-to-treat patients with CLL when used alone and in combination with rituximab, raising the prospect of a promising new therapy for elderly and frail patients who currently have few viable options.
Read More
Pomalidomide Labeled an Advance in Multiple Myeloma
December 9th 2012The combination of pomalidomide and a steroid significantly improved outcomes for patients with multiple myeloma, marking what researchers say is a notable advancement for a sizable proportion of those treated for the disease.
Read More
Ponatinib Stimulates ‘Powerful’ Response in Treatment-Resistant Leukemias
December 8th 2012Researchers have demonstrated that ponatinib can overcome a wide range of mutations that cause treatment resistance—including the stubborn T315I mutation—in all stages of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Read More